Celularity Comments on CMS Withdrawal of Skin Substitute Local Coverage Determinations
ByAinvest
Friday, Dec 26, 2025 8:31 am ET1min read
CELU--
Celularity CEO Dr. Robert J. Hariri comments on CMS' withdrawal of skin substitute Local Coverage Determinations (LCDs) that were set to take effect on January 1, 2026. The withdrawal eliminates Medicare coverage for 158 skin substitute products, but Celularity's Biovance and Biovance 3L remain eligible. Dr. Hariri highlights real-world evidence demonstrating the effectiveness of Biovance in treating chronic wounds, and notes that the company's manufacturing process and flat Medicare reimbursement rate of $127.28 per square centimeter will not impact operations.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet